Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
Purple Biotech Ltd. (PPBT) appointed director and former Chief Executive Officer Isaac Israel as Interim Chief Executive Officer, effective October 5, 2026, pending appointment of a permanent Chief Executive Officer. Israel has served on the Board since October 2012 and previously served as CEO from October 2012 until July 2022 and as an advisor from October 2022.
Gil Efron will cease serving as Chief Executive Officer effective October 5, 2026, and transition to Executive Director, Head of Corporate Development, while continuing as a Board member. Israel also served as Acting Chief Executive Officer from March 2023 to August 2023, during which his advisory engagement was suspended.
PURPLE BIOTECH LTD. (PPBT) reports that all proposals presented at its Annual General Meeting of Shareholders, held on September 8, 2026 in Rehovot, Israel, were approved by the required shareholder majorities in accordance with Israeli Companies Law and the company’s articles of association.
The company also states that this report on Form 6-K, including its exhibits, is incorporated by reference into multiple previously filed registration statements on Forms S-8 and F-3, so it becomes part of those registration statements from the submission date.
PURPLE BIOTECH LTD. (PPBT) reports that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use that support its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies. This allowance strengthens protection for the modular architecture of CAPTN-3, which is designed to enable efficient generation of tri-specific antibodies by exchanging tumor-associated antigen binding domains and functional arms on a common backbone, potentially accelerating development of new oncology candidates. The platform’s lead candidate, IM1240, is advancing toward the clinic, while IM1305 is in preclinical development. The pipeline also includes additional clinical-stage assets CM24 and NT219, both of which have completed Phase 2 studies in difficult-to-treat cancers.
Purple Biotech Ltd. has updated institutional ownership information for its Ordinary Shares, no par value. G1 Execution Services, LLC and Susquehanna Securities, LLC jointly report 26,532,000 Shares beneficially owned in aggregate, representing 1.4% of the class, based on 1,864,548,218 Shares outstanding as of May 20, 2026.
For G1 Execution Services, LLC, the reported holdings consist of American depositary shares (ADSs). Susquehanna Securities, LLC’s position consists of options to buy 10 ADSs and 409 ADSs. Each ADS represents 2,000 Shares. The firms state they may be deemed a group, report shared voting and dispositive power over all reported Shares, and each disclaims beneficial ownership of Shares owned directly by the other.
Purple Biotech Ltd. furnished an updated August 2026 corporate presentation outlining its oncology pipeline and CAPTN-3 tri-specific antibody platform. The lead asset IM1240 (capped CD3x5T4xNKG2A) is expected to enter first-in-human trials in 2027 after GLP toxicology and IND submission in 2026, with Phase 1 dose-escalation and expansion cohorts planned across multiple 5T4-positive solid tumors and a key catalyst from Phase 1 results starting in 1H 2028.
The CAPTN-3 platform combines masked T-cell engagement with NK-cell activation, showing strong preclinical anti-tumor activity and a roughly 300× improved safety profile versus a non-masked comparator, plus improved pharmacokinetics. A second CAPTN-3 asset, IM1305 (capped CD3xTROP2xNKG2A), has demonstrated dose-dependent, durable tumor regression in preclinical models. The presentation also highlights clinical proof-of-concept for CM24 in second-line pancreatic ductal adenocarcinoma, with higher response and survival measures versus chemotherapy alone, and early clinical activity for NT219 in head and neck cancer, for which a Phase 2 trial began in 2025. Cash was reported at $6 as of June 30, 2026 with runway into mid-2027.
Purple Biotech Ltd. reported second-quarter 2026 results alongside progress on its CAPTN-3 immunotherapy platform. New preclinical data for lead tri-specific antibody IM1240, presented at the 2026 EACR Congress, supported its anti-tumor activity, safety, pharmacokinetics and broad therapeutic window, with first-in-human studies aimed for 2027.
Total cash, cash equivalents and short-term deposits were $6.1 million as of June 30, 2026, which management estimates will fund operations through mid-2027. For the quarter, research and development expenses were $0.7 million and general and administrative expenses were $0.6 million, leading to an operating loss of $1.3 million. A non-cash gain from revaluation of outstanding warrants contributed to net income of approximately $0.4 million, while adjusted net loss, excluding warrant revaluation and share-based compensation, was $1.2 million. In the first half of 2026 the company raised $2.3 million in gross proceeds from ADS issuances and continues to advance IM1240, preclinical candidate IM1305, and clinical-stage assets CM24 and NT219, whose further development depends on partnering or investment.
Purple Biotech Ltd. is convening an Annual General Meeting on September 8, 2026 in Rehovot, Israel, for holders of ordinary shares and ADSs of record on August 3, 2026. Shareholders will vote on three items: electing Gil Efron and Yael Margolin as second‑class directors through the 2029 meeting; approving Efron’s new compensation as he steps down as Chief Executive Officer for health-related reasons and moves to a part‑time role as Executive Director, Head of Corporate Development; and adopting an amended and restated compensation policy for executive officers and directors.
Efron’s proposed package includes a monthly salary of NIS 40,000 (approximately $13,000), a car or allowance, and annual equity awards of up to 40,500,000 options and 40,500,000 RSUs, vesting over three years with accelerated vesting on certain terminations or a merger/sale. The updated compensation policy largely continues the existing framework while clarifying monitoring responsibility, allowing flexibility to extend vesting (including on change of control), and aligning change thresholds with Israeli Securities Authority guidance and U.S. clawback requirements.
Purple Biotech Ltd. filed a report to share an updated June 2026 corporate presentation highlighting its immuno-oncology pipeline and financial position. The company is developing CAPTN-3, a tri-specific antibody platform that engages both T cells and NK cells using a masking technology designed to improve safety while maintaining anti-tumor activity.
Lead candidate IM1240 (capped CD3 x 5T4 x NKG2A) is expected to enter first-in-human trials in 2027, with a Phase 1 study planned across several 5T4-expressing solid tumors and a key catalyst from study results starting from the first half of 2028. Preclinical data show up to 300-fold higher tolerated dosing versus a non-capped comparator and dose-proportional pharmacokinetics in non-human primates.
The presentation also describes second CAPTN-3 program IM1305 (capped CD3 x TROP2 x NKG2A), antibody CM24 targeting CEACAM1 with Phase 2 proof-of-concept data in pancreatic cancer, and small-molecule NT219 targeting IRS1/2 and STAT3 in head and neck cancer. As of March 31, 2026, Purple Biotech reported cash of $6.4 million, which it states provides runway into the first half of 2027.
Purple Biotech Ltd. reported new preclinical results for its lead CAPTN-3 candidate IM1240, presented at the EACR 2026 cancer research congress. In non-human primates, a toxicology study showed IM1240 had an 8-fold longer half-life, 16-fold greater exposure and a markedly improved cytokine-release safety profile versus a non-capped variant, supporting a broad therapeutic window and plans to move into first-in-human testing in 2027.
IM1240 demonstrated anti-tumor activity in patient-derived tumors resistant to PD-1 and standard chemotherapy across head and neck, bladder and lung cancers, with the NKG2A arm identified as critical for efficacy. In non-small cell lung cancer explants, IM1240 triggered immune remodeling, including formation of mature tertiary lymphoid structures, increased CD8 T and NK cells, and reduced regulatory T cells, consistent with effective anti-tumor immune responses.
Purple Biotech Ltd. filed a Form F-3 registration statement to register up to $200,000,000 of securities under a shelf offering.
The registration specifically includes an at-the-market program under a Sales Agreement with H.C. Wainwright for up to $824,331 of ADSs; the ADS ratio is 1 ADS = 2,000 ordinary shares. The company reports a public float of approximately $4.9 million.